Paediatric thyroid cancer is a rare disease, with well under 15% of all differentiated thyroid cancers (DTCs) being diagnosed in childhood.
Efficacy and Safety of Radioiodine in the Treatment of Disseminated Differentiated Thyroid Cancer in Children
Paediatric thyroid cancer is a rare disease, with well under 15% of all differentiated thyroid cancers (DTCs) being diagnosed in childhood.
However, as in adults DTC is the most common endocrine malignancy. DTCs account for ~10% of malignant tumours and ~35% of carcinomas in children. 1 In the US, ~350 people <20 years of age are diagnosed with thyroid carcinoma each year.
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Although DTC in paediatric patients frequently presents with metastases (60-80% nodal and 10-20% distant), the presence of metastases does not seem to have a negative impact on overall survival. Five-year survival is about 99% (95% confidence interval [CI] 95-100%) and more than 90% of patients survive for 20 years after diagnosis. 2 The indolent nature of this disease, together with its low incidence, makes it difficult to determine optimum treatment strategies, which usually include surgery, radioiodine and thyroid hormone therapy. Although there is almost unequivocal agreement that total or near-total thyroidectomy should be the initial treatment in childhood DTC, [3] [4] [5] there are still many controversies about radioiodine application. This article discusses key aspects of radioiodine treatment in paediatric DTC, with the emphasis on its benefits and risks and the recent use of recombinant human thyrotropin-stimulating hormone (rhTSH) in this group.
Use of Radioactive Iodine in Differentiated Thyroid Cancer
Radioiodine remains the mainstay of post-operative treatment of DTC and has been used for more than 60 years. 6 It is used both in patients without any signs of persistent disease as an adjunct to surgical treatment and to treat patients with disseminated or locally inoperable disease. In the first case, radioiodine treatment has to ablate any residual normal thyroid tissue in order to facilitate the follow-up and early detection of persistent or recurrent disease by measurement of serum thyroglobulin (with or without TSH stimulation) or radioactive iodine scanning. Traditionally, this kind of radioiodine treatment has been called 'thyroid ablation.' Another goal of ablation is to destroy any residual microscopic thyroid cancer foci in an effort to decrease the risk of recurrence and disease-specific mortality. In these settings it is a typical adjuvant cancer treatment. Radioiodine is also an effective treatment for persistent and metastatic DTC.
Benefits of Radioactive Iodine in Children

Adjuvant Radioiodine Treatment Decreases the Risk of Differentiated Thyroid Cancer Recurrence in Children
The recurrence rate of DTC in children ranges from 7 to 35% 7-13 and is highest in studies with the longest observation times. 7, 9, 13 In a large retrospective study including more than 1,528 patients with 16.6 years of follow-up, Mazzaferri and Massoll 14 reported a recurrence rate approaching almost 40% in patients with PTC diagnosed <20 years old; this is almost twice the recurrence rate in patients diagnosed between 20 and 50 years of age. This high recurrence rate is underscored by the report that the risk of death in paediatric DTC is almost 10 times higher in cases of recurrent disease.
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It was recently demonstrated that post-operative radioiodine therapy can decrease this high number of locoregional recurrences. 16 In a multivariate analysis of 235 patients with thyroid cancer diagnosed <18 years of age, it was shown that radioiodine therapy decreased the risk of thyroid-bed recurrence by a factor of 11 and in lymph nodes by a factor of three. Similarly, in a univariate analysis Chow and post-operatively (p=0.001). Ten-year locoregional failure-free survival in children without distant metastases at diagnosis was 86.5% compared with 71.9% for those not treated with radioiodine (p=0.04).
It was recently demonstrated that although pre-pubertal children often suffer from advanced disease (e.g. extrathyroid extension, lymph node and distant metastases) compared with pubertal adolescents, disease outcome is similar in both groups if adequate treatment consisting of thyroid surgery and radioiodine is applied.
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These results are in agreement with a meta-analysis of remnant ablation outcomes in DTC patients of all ages, which determined that radioiodine reduced the risk of locoregional and distant recurrence.
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Nevertheless, it should be stressed that not all authors agree on the beneficial role of radioiodine in the post-surgical management of childhood DTC as there are studies in which radioiodine did not affect the outcome in children with DTC. 13, 19 In a recent large retrospective study of 215 DTC patients <21 years of age at DTC diagnosis, Hay and colleagues 13 did not find any difference in incidence of recurrence in children regardless of whether they had been treated with adjuvant radioiodine treatment after total or near-total thyroidectomy.
Adjuvant Radioiodine Treatment Increases the Accuracy of Disease Staging
Another issue is that a substantial number of paediatric patients can only be properly staged on the basis of a radioiodine scan, preferably after high radioiodine activity. In about 20-50% of paediatric DTC patients affected with distant metastases, only a post-ablation total-body scan enables the detection of lung metastases. The high prevalence of functional metastases in pediatric DTC results in very effective radioiodine treatment. In publications to date, this modality achieved complete remission in the majority of children with lung metastases (see Figure 1 ). There are limited data on the use of rhTSH for radioiodine treatment in this age group. [33] [34] [35] Ten children were evaluated for the success rate of thyroid remnant ablation with rhTSH-aided radioiodine treatment.
In five cases treatment resulted in complete loss of radioiodine uptake and low thyroglobulin levels. In two patients there was some persistent, minimal (<1%) uptake in the thyroid bed with low thyroglobulin level without indications for repeated radioiodine therapy. In one patient, thyroid remnant ablation was successful but led to an increasing thyroglobulin level. In two patients (20%) ablation was unsuccessful and repeated radioiodine therapy was necessary.
The largest group of children and adolescents diagnosed or treated with rhTSH was described recently by Luster and colleagues 36 in a multicentre, retrospective study. In 40 patients, rhTSH preparation was used for radioiodine thyroid remnant ablation (in eight patients with advanced disease). In the other cases, rhTSH was used for diagnostic purposes. As the report focused on the tolerability of the drug and its serum TSH effect, the results of ablation are unfortunately unknown. After the standard schedule of rhTSH administration in most rhTSH courses, peak TSH concentration on the third day after the first rhTSH injection was ≥25mU/l in 144 (98%) of 147 patients and was inversely correlated with the body mass index of patients. Clinical adverse effects related to rhTSH were reported in 12% of cases. The most commonly reported adverse effects in descending frequency were nausea, vomiting, headache, rash, fatigue and breathing difficulties, none of which had an incidence >5%. There was no relationship between rhTSH dosing or peak serum TSH levels and the occurrence of adverse effects.
The main advantage of rhTSH-aided radioiodine therapy in children is the reduced total-body irradiation. Compared with hypothyroidism, the euthyroid state at the time of 131 I administration increases renal radioiodine clearance and decreases both whole-body and blood radiation dose, which is a surrogate measure of bone marrow radiation. 37, 38 This should, at least theoretically, decrease the risk of radiation-related side-affects in children -mainly the risk of secondary neoplasm. The results of a recent study 39 in which the frequency of lymphocyte chromosomal rearrangements after radioiodine treatment was significantly lower after preparation with rhTSH than in the withdrawal group favours this hypothesis. This indicates that rhTSH reduces the potential risk of chromosomal aberration associated with blood irradiation. Of note is the fact that rhTSH preparation also allows avoidance of the adverse physical and neuropsychological side effects connected with hypothyroidism -a very important issue in a young, developing person.
The main concern in rhTSH-aided radioiodine therapy is the risk of an insufficient radiation dose to target tissues, particularly in a group of patients where up to 20% can suffer from distant metastases at diagnosis. Indeed, in dosimetric evaluation of thyroid remnant ablation, radioiodine uptake at 48 hours was lower in patients treated with rhTSH then with TSH withdrawal; however, this was compensated for by a longer radioiodine effective half-time in remnants and resulted in similar remnant residence times in both groups. 37 Recent clinical data have showed that in the short term the recurrence rate is similar between patients with endogenous and exogenous rhTSH stimulation.
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The application of rhTSH for radioidine treatment has also raised concerns about decreased activity due to the iodine content of L-T4
preparations. Despite this, a recent study indicates that the body iodine content is not an important determinant of thyroid ablation when preparing patients with either thyroid hormone withdrawal or rhTSH.
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Radioactive Iodine Activities
No consensus has been reached regarding the 131 I activities that provide maximum efficacy with minimum toxicity for adjuvant radioiodine treatment in children and adolescents with DTC.
Some centres 3,7 give 3.7MBq/kg (1mCi/kg) bodyweight. However, bodyweight-based formulas seem to produce rather low activities, and body-surface-area-based formulas may be more appropriate.
Extensively analysing variable dosing issues in paediatric patients, Reynolds 42 noted that red bone marrow absorbs a greater dose of 131 I in children than in adults, since the same activity is distributed to smaller organs and shorter distances between the organs increase the cross-radiation. According to his diagrams for calculating appropriate activity, a 15-year-old should receive about five-sixths of the adult activity. Younger children need further reductions, e.g. half of the adult activity for a 10-year-old and one-third of the activity for a five-year-old.
Another approach 43 is to adjust the ablation activity according to the 24-hour thyroid-bed uptake as well as administering it according to bodyweight: <5% uptake would warrant an activity of 50MBq/kg, whereas a 5-10% uptake would warrant an activity of 25MBq/kg and a 10-20% uptake would warrant an activity of 15MBq/kg.
None of these strategies has proved to be superior to the others. 
Side Effects of Radioiodine Activity
There are two main concerns about the use of (internal or external) radiation therapy in children: the induction of secondary cancers and fertility disorders.
Secondary Malignancies
To the authors' knowledge there have been 21 reports of secondary malignancies after therapeutic radioiodine use in children and adolescents. 13, 16, 30, 48 
Conclusions
Treating children with DTC is a challenge, given that children frequently present with advanced disease yet very rarely die from it.
All of the available data on radioactive iodine in the management of 
